• Go to navigation
  • Go to content
Welcome to Zomig.info!

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca
  • Zomig
  • Zomig Rapimelt
  • Zomig Nasal Spray

Main navigation

  • Home
  • Is it Migraine?
  • Learn About Migraine
  • Treating Migraine
  • Help For Your Migraine Patients
  • Scientific Opinions
    • Scientific Posters
      • Zolmitriptan
      • Zomig Rapimelt
      • Zomig Nasal Spray
  • Learn about Zomig
  • eDetailing
  • Prescribing Information
  • Migraine Glossary and Useful Links
  • References
  • About AstraZeneca
  • Sitemap

You are here

  • Home
  • Scientific Opinions
  • Scientific Posters
  • Zomig Nasal Spray

  • Zolmitriptan is effective for the acute treatment of cluster headache: a systematic review

  • A single dose of zolmitriptan nasal spray is efficacious over multiple attacks

  • Zolmitriptan nasal spray demonstrates fast, reliable efficacy in the acute treatment of migraine

  • Zolmitriptan nasal spray improves patient satisfaction by providing fast and effective relief from migraine symptoms

  • Zolmitriptan nasal spray is a highly effective migraine therapy that is preferred by patients: a post-marketing surveillance study

  • The speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine

  • Patient experience influences formulation preference: Results of three prospective studies with zolmitriptan

  • Intranasal zolmitriptan 5 mg is well tolerated and effective during long-term use for the acute treatment of multiple migraine attacks

  • High levels of satisfaction in patients treating migraine with zolmitriptan nasal spray in a real life setting: results from phase 2 of the REALIZE study

  • Efficacy of zolmitriptan nasal spray according to severity of migraine and timing of drug administration

  • Pages
  • 1
  • 2
  • Next

Not signed in



  • Register
  • Forgotten password?

Page tools

  • Print
  • Bookmark this page

Clinical Product Summary

  • Zomig Nasal Spray
  • Zomig Rapimelt

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2008